Efficacy News and Research

RSS
Avinger completes patient enrollment in CONNECT trial to treat CTOs linked with PAD

Avinger completes patient enrollment in CONNECT trial to treat CTOs linked with PAD

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Positive results from exenatide phase 2 study in patients with type 2 diabetes

Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

Scientists identify chemical compound that may lead to cancer-fighting drugs

Scientists identify chemical compound that may lead to cancer-fighting drugs

Ohio officials seek federal permission for use of propoxur to halt bedbug infestations

Ohio officials seek federal permission for use of propoxur to halt bedbug infestations

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

FDA approves BENLYSTA for active, autoantibody-positive systemic lupus erythematosus

KineMed extends collaboration with BMY to identify and characterize Alzheimer's biomarkers

KineMed extends collaboration with BMY to identify and characterize Alzheimer's biomarkers

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Adamis submits APC-100 IND to FDA for treatment of prostate cancer

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

'Cross-talk' between two major biological pathways may hold a clue for chronic pain treatment

'Cross-talk' between two major biological pathways may hold a clue for chronic pain treatment

ITMNs can reduce Japanese Encephalitis transmission to humans

ITMNs can reduce Japanese Encephalitis transmission to humans

Unique gene therapy to combat Parkinson's disease

Unique gene therapy to combat Parkinson's disease

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Patrys succeeds in obtaining commercial yields for its anti-cancer antibody therapeutic

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

Recent rituximab trial with TNF inhibitors reports no new safety risks in patients with RA

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.